ÂÜÀòÂÒÂ×

Tommy Leggett is a seasoned finance executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving on the Board of Directors at Clover Biopharmaceuticals since April 2021, Tommy has also held the position of Chief Financial Officer at Affinia Therapeutics from December 2021 to May 2024 and at Black Diamond Therapeutics from September 2019 to December 2021. Additional roles include Board of Directors at Research Alliance Corp. II and Chief Financial Officer for Axcella, demonstrating strong leadership in financial strategy and development. Prior experience encompasses senior roles at Purdue Pharma L.P., UBS Investment Bank, Lazard Freres, and JPMorgan, alongside an academic background that includes an MBA in Finance from The Wharton School and a BA in Economics from Columbia University.